The Munich-based biopharmaceutical startup Immunic is pleased to receive financial support of 653,535 euros from the InnoMuNiCH project of the German Federal Ministry of Education and Research (BMBF).
The project is managed by BioM Biotech Cluster Development and supported by the BMBF as part of the 'Internationalization of Leading-Edge Clusters, Future Projects, and Similar Networks' initiative. The project aims to accelerate global biopharmaceutical innovations by pooling German and Japanese research and development expertise.
International research project for Immunic
During the three-year funding period, Immunic will collaborate with a Japanese pharmaceutical company, Kyoto University, and Quattro Research in a research project to investigate the effects of small molecule drugs on cellular metabolism, as well as their influence on the development of T helper cells and the corresponding regulation of relevant proteins. The project started on August 1 and ends on July 31, 2022. Hella Kohlhof, Chief Scientific Officer of Immunic says:
“One of the biggest challenges in developing small molecule therapies for chronic inflammatory and autoimmune diseases is the lack of selectivity, which often leads to a variety of serious side effects.”
She further adds:
"Th1 and Th17 cells play a significant role in diseases such as multiple sclerosis, inflammatory bowel disease, and psoriasis, among others. In this project, we are combining Immunic's expertise in intracellular metabolism with the extensive experience and resources of our partners. We hope that the results will lead to the development of new therapeutic options for underserved patient populations and that the identification of qualified biomarkers will enable us to better define and target these patient groups."
